Novartis Pharmaceuticals Corporation Industry-Expert Theater - Advancing Treatment in mCRPC: What Radiation Oncologists and Nuclear Medicine Specialists Should Know About PLUVICTO, the First and Only PSMA-Targeted Therapy After One ARPI